Back of napkin calcs.
$150k in 2 weeks, $300k a month, $1.2m in 4 months of winter. Double distribution numbers and we have $2.4m, assuming similar sales numbers.
This sort of revenue extends cash flow, and along with potential success of FebriDx could lead to cash flow positive in 6 months or so.
This is a company making turnaround. From $1.40 to 1c, back to a speccy $1+ stock.
Ann: Commercial Operations Update Webinar Presentation, page-18
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
